Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy

Prior treatment

• Received any systemic anti-tumor therapy for target lesions before induction chemotherapy and immunotherapy;
• Previously experienced head and neck radiation therapy;
• Subjects who have used corticosteroids (\>10 mg/day prednisone or other equivalent hormones) or other immunosuppressive agents for systemic treatment within 1 month before enrollment. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy at therapeutic doses of prednisone ≤10 mg/day are permitted;
• Patients with pleural effusion, pericardial effusion or ascites that need to be drained with clinical symptoms, or who have received serous cavity effusion drainage for the purpose of treatment within 2 weeks before enrollment;

Other illness

• Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ)
• Severe comorbidities including myocardial infarction, arrhythmia, cerebral vascular disease, ulceration disease, mental disease and uncontrolled diabetes

• The subjects are not limited by gender, age from 18 to 75 years old;
• Histopathologically confirmed squamous cell carcinoma of the head and neck cancer;
• Locally advanced squamous cell carcinoma diagnosed as T3-4 or N+ stage according to AJCC 8th edition staging;
• ECOG score 0-1;
• without distant metastasis;
• received induction chemotherapy plus immunotherapy, followed by surgery
• The expected survival is expected to be no less than 6 months.
• No contraindications to chemotherapy, immunotherapy, and radiotherapy;